Recursion Pharmaceuticals (NASDAQ: RXRX) and Exscientia (NASDAQ: EXAI) made waves on Aug. 8 when they announced plans to merge into one business, forming the world's largest biotech devoted to doing drug development empowered by artificial intelligence (AI). The deal is expected to close sometime in early 2025. And now the bull thesis for Recursion's stock is more formidable than it was before.

Here's what you need to know about what this merger is going to accomplish for shareholders, and why it's probably going to be a net positive in the long run.

There are a handful of upsides to Recursion merging with Exscientia.

Continue reading

Source Fool.com